Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

$224.69 +0.42 (+0.19%)

As of 02:31 PM Eastern

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
0

Buy
7

Based on 7 Wall Street analysts who have issued ratings for Becton, Dickinson and Company in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for BDX.

Consensus Price Target

$278.29
23.85% Upside

According to the 7 analysts' twelve-month price targets for Becton, Dickinson and Company, the average price target is $278.29. The highest price target for BDX is $290.00, while the lowest price target for BDX is $270.00. The average price target represents a forecasted upside of 23.85% from the current price of $224.69.

Get the Latest News and Ratings for BDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Becton, Dickinson and Company and its competitors.

BDX Analyst Ratings Over Time

Type	Current Forecast 3/5/24 to 3/5/25	1 Month Ago 2/4/24 to 2/3/25	3 Months Ago 12/6/23 to 12/5/24	1 Year Ago 3/6/23 to 3/5/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$278.29	$283.00	$283.50	$279.17
Forecasted Upside	23.85% Upside	14.31% Upside	27.56% Upside	19.52% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

BDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Becton, Dickinson and Company Stock vs. The Competition

Type	Becton, Dickinson and Company	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	23.85% Upside	22,958.00% Upside	16.89% Upside
News Sentiment Rating	Positive News See Recent BDX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/14/2025	Barclays 3 of 5 stars	Travis Steed Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$278.00 ➝ $279.00	+24.01%
1/28/2025	Piper Sandler 2 of 5 stars	Jason Bednar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$275.00 ➝ $280.00	+12.65%
10/1/2024	Evercore ISI 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$286.00 ➝ $290.00	+20.29%
10/1/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$255.00 ➝ $275.00	+14.08%
8/2/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$275.00 ➝ $270.00	+12.55%
7/26/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$270.00 ➝ $280.00	+17.80%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$274.00	+21.82%
12/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$310.00 ➝ $280.00	+17.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:32 PM ET.

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 2, 2025. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

Becton, Dickinson and Company
Bull Case

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

Becton, Dickinson and Company reported earnings per share of $3.43, exceeding analysts' expectations of $3.00, indicating strong financial performance and potential for growth.
The company has a solid net margin of 8.47% and a return on equity of 15.74%, showcasing effective management and profitability, which are attractive traits for investors.
Recently, Becton, Dickinson and Company announced a quarterly dividend of $1.04 per share, translating to an annualized yield of 1.84%. This consistent dividend payment can provide a steady income stream for investors.
Insider transactions indicate confidence in the company, with executives recently selling shares but still holding significant positions, suggesting they believe in the company's future prospects.
As of now, the stock price is approximately $235.00, which may be considered attractive for investors looking for opportunities in the medical instruments sector.

Becton, Dickinson and Company
Bear Case

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

Insider sales have occurred recently, with a total of 10,544 shares sold worth over $2.3 million, which could signal a lack of confidence in the stock's short-term performance.
The company has a payout ratio of 69.10%, which indicates that a significant portion of earnings is being distributed as dividends. This could limit the funds available for reinvestment in growth opportunities.
Despite recent growth in institutional ownership, which stands at 86.97%, any significant sell-off by these large investors could negatively impact the stock price.
Market volatility and economic uncertainties could pose risks to the healthcare sector, potentially affecting Becton, Dickinson and Company's performance.
Recent insider transactions show a decrease in positions, with one executive selling 788 shares, which may raise concerns about the company's future outlook among investors.

BDX Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Becton, Dickinson and Company is $278.29, with a high forecast of $290.00 and a low forecast of $270.00.
: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDX shares.
: According to analysts, Becton, Dickinson and Company's stock has a predicted upside of 23.85% based on their 12-month stock forecasts.
: Becton, Dickinson and Company has been rated by research analysts at Barclays, and Piper Sandler in the past 90 days.
: Analysts like Becton, Dickinson and Company more than other "medical" companies. The consensus rating for Becton, Dickinson and Company is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BDX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:BDX) was last updated on 3/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Becton, Dickinson and Company (BDX) Stock Forecast & Price Target